Oncolytics Biotech Inc.
ONCY
$0.90
$0.022.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.30M | -21.84M | -22.69M | -23.14M | -20.32M |
| Total Depreciation and Amortization | 260.20K | 269.70K | 273.40K | 297.00K | 318.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.68M | 2.21M | 1.71M | 560.80K | -2.99M |
| Change in Net Operating Assets | 442.00K | 1.73M | 2.04M | 2.61M | 4.42M |
| Cash from Operations | -18.92M | -17.63M | -18.66M | -19.67M | -18.57M |
| Capital Expenditure | -9.40K | -27.80K | -141.10K | -175.20K | -173.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Investing | -9.40K | -27.80K | -141.10K | -175.20K | -173.10K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -406.00K | -385.00K | -348.00K | -348.00K | -352.00K |
| Issuance of Common Stock | 20.60M | 16.45M | 12.29M | 7.74M | 4.13M |
| Repurchase of Common Stock | -- | -- | -- | -- | -882.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.45M | -1.64M | -915.00K | -751.00K | 2.15M |
| Cash from Financing | 13.38M | 10.25M | 7.81M | 4.81M | 3.71M |
| Foreign Exchange rate Adjustments | 350.70K | 14.50K | 612.80K | 1.16M | 46.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.20M | -7.40M | -10.38M | -13.87M | -14.99M |